At Friday’s close, the stock market in London showed more activity compared to New York. The FTSE 100 ended the day down by 0.22%. The top performer was the mining firm Antofagasta, which
At Friday’s close, the stock market in London showed more activity compared to New York. The FTSE 100 ended the day down by 0.22%. The top performer was the mining firm Antofagasta, which
Bens Creek (BEN) and Horizonte Minerals (HZM) both companies delivered the following RNS: At the request of the company, trading on AIM for the under-mentioned securities has been temporarily suspended from 16/05/2024 7:30am,
Marula Mining (AQSE: MARU) an African-focused mining and development company, has signed a long-term offtake agreement with Fujax UK Ltd for spodumene ore and concentrate from the Blesberg Lithium and
88 Energy (88E) advised that it has received US$2.0 million in funds from its Project Phoenix JV partner Burgundy Xploration, LLC as part settlement of the US$3.745 million in unpaid cash
ValiRx Plc (AIM: VAL), a life science company focusing on cancer therapeutics and women’s health, announces that ValiSeek Limited (“ValiSeek”), has entered into an exclusive Option Agreement to license VAL401
Neometals (NMT) announced the successful completion of the purification phase of its Lithium Chemical pilot trial. The Purification Testwork, conducted on a brine feed source, has confirmed earlier bench-scale testing
It has been a solid week for small caps in general, with the AIM All-Share Index increasing by 1.9% to 765.79p since the start of the week. Positive inflation data
Audioboom (BOOM), the podcast company, announced its unaudited half-year results for the six months ended 30 June 2023.
In the wider market, the AIM-All Share index had a flat week, adding 0.02% to 794 points, falling short of its benchmark, the FTSE 100, which rose 1.4% to 7,670.
San Leon (SLE), the oil and gas production company, announced a further update in relation to its proposed refinancing and its current financial situation.
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.